AIMD News & Events

Ainos, announced continued validation testing of its AI Nose platform within advanced semiconductor front-end wafer fabrication environments. As part of this qualification phase, Ainos plans to install approximately 200 AI Nose systems across targeted front-end facilities in the first quarter of 2026 for technical validation. These deployments would set the foundation for commercial integration in front-end wafer fabrication facilities, subject to customer review and formal commercial approval. Front-end wafer fabrication represents one of the most demanding industrial environments globally, requiring precise chemical process control and continuous cleanroom monitoring. Ainos believes the expanded validation reflects growing interest in integrating scent intelligence into semiconductor manufacturing systems. This front-end initiative builds on Ainos' broader deployment roadmap within the semiconductor ecosystem. Ainos is also executing Phase 1 deployment of 1,400 AI Nose systems with its back-end semiconductor customer. That phase represents approximately $2.1 million in total value under a three-year subscription framework and targets completion in the second quarter of 2026. The broader roadmap contemplates deployment of up to 20,000 AI Nose systems across the back-end customer's facilities, subject to technical validation and contractual conversion. If fully executed, the program could approach $10 million in annual subscription value.

Ainos issued a letter from Chairman, President and CEO Eddy Tsai, which read in part, "I'm proud to share that the AI Nose platform is transitioning from validation-stage pilots into structured industrial deployment. The confirmed initial order of 1,400 AI Nose systems activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million. This milestone marks our progression from proof-of-concept validation to revenue-generating implementation within semiconductor manufacturing environments. This also reflects our vision to expand AI Nose from healthcare into the broader industrial market. The broader roadmap contemplates phased deployment of up to 20,000 AI Nose systems across customer facilities. If fully executed over time, this framework could support annual order values approaching $10 million. Advancement into subsequent phases remains subject to staged technical validation and formal contractual conversion with our customer...In parallel, AI Nose is undergoing validation testing within advanced semiconductor front-end fabrication facilities - among the most technically demanding industrial environments in the world. These evaluations will set the foundation for commercial integration in advanced wafer fabrication facilities. Successful validation would expand our industrial integration opportunities within capital-intensive wafer fabrication environments. We remain focused on disciplined execution, subscription activation, and scalable infrastructure expansion as we position scent as the next AI token - advancing the smell language model (SLM), strengthening Smell ID libraries, and building SmellTech, powered by AI Nose, as a foundational sensing infrastructure for industrial AI systems."

Ainos announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the installation of up to 20,000 AI Nose units within semiconductor manufacturing environments. The framework under a Memorandum of Understanding with ASE Technology Holding, outlines a multi-phase expansion strategy designed to integrate digital olfaction, powered by the AI Nose platform, into ASEH's semiconductor packaging and testing facilities. Ainos is executing the first phase of deployment that includes: confirmed order of 1,400 AI Nose units under a three-year subscription structure totaling approximately $2.1M; Ainos has received $350,000 in customer deposit payments; Ainos is targeting to complete the first phase deployment by the end of Q2 2026. Following phase one: Phase two contemplates deployment of 5,000 AI Nose units; Phase three contemplates deployment of up to 15,000 AI Nose units Advancement into subsequent phases remains subject to milestone validation and contractual progression under the strategic framework. In parallel, Ainos is deploying AI Nose within advanced front-end semiconductor wafer fabrication facilities for validation testing. These deployments are part of technical qualification and remain subject to customer review and formal commercial approval prior to potential conversion into revenue-generating programs.

Ainos announced interim results from its ongoing open-label, multi-dose clinical trial evaluating VELDONA, a low-dose oral interferon alpha formulation, for the treatment of Feline Chronic Gingivostomatitis , a severe, chronic inflammatory oral disease in companion animals. The study is designed to enroll 12 client-owned cats diagnosed with FCGS across two dosing cohorts. The interim analysis includes the first six treated subjects. Enrollment remains ongoing. The primary disease activity assessment utilized the Stomatitis Disease Activity Index, a composite score integrating: Veterinary assessment of oral inflammation; Body weight changes; Owner-reported activity and feeding behavior. At Week 6: The majority of subjects demonstrated reductions in total SDAI scores. Directional improvement in overall disease activity was observed across the cohort. No clinically significant rebound was observed through Week 14 follow-up. Local oral inflammation scores demonstrated consistent and statistically significant improvement: 6 of 6 cats showed lower oral inflammation scores at Week 6 compared to baseline. Mean improvement reached approximately 38% at Week 6. 66.7% of subjects achieved greater than or equal to30% clinically meaningful improvement. Wilcoxon signed-rank testing demonstrated statistical significance. At Week 14 follow-up, mean improvement in oral inflammation increased to approximately 45%, suggesting sustained benefit after completion of the six-week treatment course. Notably, one subject that did not undergo full-mouth dental extraction achieved measurable clinical improvement during interferon therapy, supporting a therapeutic effect independent of surgical recovery and consistent with an immunomodulatory mechanism. Ainos plans to continue enrollment toward the full 12-subject target and further evaluate dose-response relationships, durability of effect, and safety outcomes in the complete dataset. Comparative hematology and serum biochemistry analyses between baseline and Week 6 demonstrated: Liver enzymes remained within normal limits. Renal function markers remained stable without dose-related deterioration. No persistent leukocyte abnormalities or evidence of immunosuppression were observed. No dose-related toxicity trends were observed. VELDONA was well tolerated in all six subjects, with no clinically significant safety signals identified in this interim analysis.